|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,2
,2



,3
*Department of Immunology,
Department of Biochemistry, and
Department of Pathology, Medical School and Diabetes Research Center, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea; and
Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
TNF receptor 1 can activate signaling pathways leading to the activation of NF-
B. A20, an NF-
B-inducible protein, negatively regulates these signaling pathways and acts as an anti-inflammatory mediator. Therefore, A20 is viewed as a potential therapeutic target for inflammatory disease. In this study, we examined the effect of A20 on an OVA-induced allergic airway inflammation model in mice. We used an adenovirus containing A20 cDNA (Ad-A20) that was delivered intratracheally before OVA challenge. Single administration of Ad-A20 reduced airway inflammatory cell recruitment and peribronchiolar inflammation and suppressed the production of various cytokines in bronchoalveolar fluid. In addition, Ad-A20 suppressed mucus production and prevented the development of airway hyperresponsiveness. The protective effect of Ad-A20 was mediated by the inhibition of the NF-
B signaling pathway. Taken together, our results suggest that the development of an immunoregulatory strategy based on A20 may have therapeutic potential for the treatment of allergic asthma.
3 Address correspondence and reprint requests to Dr. Byung-Hyun Park, Department of Biochemistry, Medical School, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea. E-mail address: bhpark{at}chonbuk.ac.kr
1 This work was supported by a grant from the Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Diabetes Research Center at Chonbuk National University (R13-2008-005-0000-0).
2 N.-I.K., H.-Y.Y., and Y.-R.L. contributed equally to this study.
This article has been cited by other articles:
![]() |
I. Martinez-Forero, A. Rouzaut, A. Palazon, J. Dubrot, and I. Melero Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation Clin. Cancer Res., November 15, 2009; 15(22): 6751 - 6757. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |